November 2, 2026
Can monthly dosing can justify a stock near record highs.
Amgen trades at roughly $466, within a few dollars of its all-time high, and is scheduled to report after the close on Tuesday, November 3, 2026. The consensus sits around $5.79 in adjusted EPS on about $10.08 billion in revenue, a thin beat above last year’s $5.64. That is almost beside the point. The trade that matters is not whether Amgen clears the bar on profit, it has beaten the consensus EPS estimate in eight consecutive quarters, it is what management says about Phase 3 obesity trials running simultaneously in one of the most violently reset markets in pharmaceutical history.
For Traders Protecting a Nest Egg
If you’re trading with money you spent decades saving, one bad options trade hurts more than it should.
The first few checks on this list are all about protecting your account before you think about anything else.
The Smart Trade Options Checklist.
Normally $29.97. Free today.
MariTide is a differentiated antibody-peptide conjugate that activates the GLP-1 receptor and antagonizes the GIPR, with a long-acting design that supports starting with monthly dosing and potentially as few as four or six doses per year. That dosing advantage is the core of Amgen’s argument. Unlike Wegovy and Zepbound, both weekly injections, MariTide combines GLP-1 activation with GIP receptor blockade and is designed for once-monthly or potentially even less-frequent dosing, which may improve adherence over time.
The backdrop could not be more loaded. Wall Street expects Novo Nordisk to report about $0.75 per ADR on revenue near $11.1 billion for Q3 2026. That compares with $1.02 per ADR on $11.79 billion a year ago, implying an earnings decline of roughly 26% and a revenue drop of about 5.9%. This is what a price war looks like when it reaches your own income statement. Novo has already announced a list-price reduction to $675 per month across Wegovy, Ozempic, and Rybelsus effective January 1, 2027, roughly half off Wegovy and about 35% off Ozempic versus prior list prices. Eli Lilly is accelerating a competing oral molecule. MariTide arrives into this disruption without a single approved product, which is precisely why the Phase 3 commentary this week carries weight that exceeds the quarterly numbers.
MARITIME-1 is studying MariTide in adults with obesity or overweight without Type 2 diabetes; MARITIME-2 covers the same population with Type 2 diabetes; and MARITIME-CV is enrolling adults with established atherosclerotic cardiovascular disease. Three concurrent studies mean three sets of enrollment updates, safety signals, and timeline disclosures. Any one of them can move the stock in either direction with no warning.
$46 Billion Is Waiting on December 11
The Pentagon wants $46 billion for a “sovereign AI Arsenal.” Bigger than Golden Dome.
A stopgap law has frozen every dollar of it until December 11.
The Arsenal runs on Elon’s AI. And Elon’s AI hinges on one tiny company he couldn’t build around.
The financials do carry one genuine headwind. Outgoing CFO Peter Griffith warned of a “meaningful sequential increase in operating expenses” in Q3, including a $100 million upfront payment tied to a business development transaction that will flow through non-GAAP R&D. Full-year non-GAAP R&D is expected to grow high single digits, which includes nine ongoing global Phase 3 MariTide trials alongside other late-stage programs. That spending pattern is rational if MariTide works at commercial scale. It is expensive turbulence if trial data disappoints.
MariTide is not the only challenger building a case around less-frequent dosing. Viking Therapeutics showed monthly maintenance preserved roughly 90% of weight loss versus 61% for placebo, setting a clinical benchmark MariTide’s Phase 3 data will now be measured against.
The Options Angle
The options market is pricing about a ±5.3% move for AMGN into Tuesday’s report, which translates to roughly $24 at current levels. Implied volatility sits in the low 30s on a 30-day basis, elevated into the event but not extreme for a stock carrying this much pipeline binary risk. For a trader who wants defined exposure to a positive MariTide update, enrollment acceleration, a clean cardiovascular signal, or a timeline that pulls forward a potential 2027 readout, a November call spread captures that catalyst while limiting premium at risk to the cost of the spread itself.
One idea. Backed by the analysts.
Join 130,000+ self-directed investors who get one trade idea a day, sourced from top Wall Street analysts and explained in plain English. Free, and a five-minute read.
Consider a bull call spread using the November $475/$495 strikes, bought before Tuesday’s close. If Amgen delivers a beat and positive trial commentary, the position benefits from both the earnings surprise and the option’s leverage. If the quarter disappoints or management guides cautiously on MariTide costs, the loss is capped at the premium paid. With a stock near all-time highs, defined risk is not a suggestion, it is the structure.
There is a second cost layer the options market may be underpricing. Pharma importers outside the MFN framework face 100% tariffs on patented drugs, a structural cost that complicates manufacturing economics for complex biologics.
The Beast Verdict
The quarterly number will come and go. What defines AMGN’s trajectory over the next twelve months is whether MariTide can sustain its positioning as a genuinely differentiated obesity drug while Novo and Lilly compete on price. MariTide’s antibody format enables monthly dosing, which could improve adherence relative to weekly injectables, though its differentiation rests primarily on that convenience rather than demonstrated superior efficacy, and its manufacturing complexity may limit cost competitiveness against peptide-based agents. That tension, real clinical utility versus a market collapsing on price, is what the next hour of conference call will begin to resolve. Position sized for the comment, not the quarter.
